GlycoMark (1,5-AG) At-Home and Finger-Prick Options

What Is GlycoMark (1,5-AG) and Why Does It Matter?

GlycoMark is the brand name for the 1,5-anhydroglucitol (1,5-AG) assay, a short-window glycemic marker cleared by the FDA in 2003 for monitoring glycemic control in people with diabetes. Unlike HbA1c, which averages glucose over 90 days, 1,5-AG turns over in roughly 1 to 2 weeks, making it sensitive to recent postprandial glucose excursions that longer-term markers completely miss.

The Biology Behind the Number

1,5-AG is a naturally occurring glucose analog found in most foods. Under normal conditions, roughly 99% of filtered 1,5-AG is reabsorbed in the renal tubule. When blood glucose rises above approximately 180 mg/dL (the renal threshold), glucose competes with 1,5-AG for the SGLT-2 transporter, driving more 1,5-AG into the urine and lowering its serum concentration. A 2008 analysis in Diabetes Care (N=1,581) confirmed that serum 1,5-AG falls sharply as postprandial glucose excursions increase, even when fasting glucose remains normal. [1]

This mechanism means 1,5-AG behaves as an indirect, inverse marker: higher serum levels indicate fewer recent spikes, while lower levels signal frequent excursions above the renal threshold.

How 1,5-AG Complements HbA1c

HbA1c is poorly sensitive to postprandial spikes in patients whose overall average glucose is near normal. A person with an HbA1c of 6.2% could still be spiking to 220 mg/dL after meals three times daily, and that signal is diluted in a 90-day average. A 2010 study in the Journal of Clinical Endocrinology and Metabolism showed that 1,5-AG identified postprandial hyperglycemia in 35% of patients whose A1c was below 7.0%. [2] The two biomarkers therefore give complementary, not redundant, information.

GlycoMark Normal Range and Optimal Targets

The reference range and the optimal (functional medicine) target are two different numbers. Knowing both matters for interpreting your result correctly.

Published Reference Ranges

The commercially available GlycoMark assay, processed through Esoterix/LabCorp, reports a reference interval of 10.7 to 32.0 mcg/mL for non-diabetic U.S. Adults. The FDA product insert defines the following clinical interpretation tiers:

| 1,5-AG (mcg/mL) | Interpretation | |---|---| | Above 19.0 | Glucose excursions rarely exceed 180 mg/dL | | 10.0 to 19.0 | Occasional excursions above 180 mg/dL | | 6.0 to 10.0 | Frequent excursions above 180 mg/dL | | Below 6.0 | Very frequent or prolonged excursions above 180 mg/dL |

The FDA product approval documentation for GlycoMark confirms these interpretive cutoffs and the assay's analytical validation. [3]

The Longevity-Medicine Optimal Target

The lower boundary of "normal" (10.7 mcg/mL) still represents a person who spikes frequently. Longevity-focused clinicians, including those practicing precision metabolic medicine, consider values above 19 mcg/mL the practical target for metabolically healthy adults. The Atherosclerosis Risk in Communities (ARIC) study, which followed 11,092 participants, found that 1,5-AG levels in the bottom quartile (below approximately 10 mcg/mL) were independently associated with a 34% higher incidence of coronary heart disease over a median 15-year follow-up. [4] That association persisted after adjusting for HbA1c, fasting glucose, and traditional cardiovascular risk factors.

The HealthRX clinical team uses the following tiered interpretation framework when reviewing 1,5-AG results:

• Above 19 mcg/mL: No dietary or pharmacologic intervention warranted on the basis of 1,5-AG alone.
• 14 to 19 mcg/mL: Targeted postprandial CGM trial (14 days) recommended to map specific spike triggers before intervening.
• 10 to 14 mcg/mL: Structured low-glycemic-load dietary protocol plus re-test in 6 to 8 weeks.
• Below 10 mcg/mL: Formal diabetes or pre-diabetes workup including OGTT; consider GLP-1 receptor agonist evaluation.

Sex and Age Considerations

Reference ranges are not meaningfully stratified by sex in the FDA-cleared assay. Age shows a modest effect: a 2015 cross-sectional analysis of 4,234 adults in the NHANES-linked dataset found a slow decline in 1,5-AG with age (roughly 0.2 mcg/mL per decade after age 40), likely reflecting reduced dietary intake of 1,5-AG-containing foods rather than renal tubular dysfunction. Those data were described in Diabetes Care. [5]

At-Home and Finger-Prick Testing: What Currently Exists

No at-home or finger-prick test for 1,5-AG is FDA-cleared in the United States as of 2025. The assay requires a liquid serum or plasma sample from a venous draw, a cold-chain shipping process, and a reference-lab immunoassay platform. This section explains why, and what the nearest practical alternatives look like.

Why a Finger-Prick Format Is Technically Difficult

1,5-AG concentration in whole capillary blood (the matrix a finger-prick device would use) is less stable than in processed serum. The molecule also exists at concentrations (in the mcg/mL range) that strain point-of-care lateral-flow sensitivity. Japanese manufacturers have developed a dry-chemistry-based 1,5-AG analyzer (the GlycoStation TS Reader, Arkray Inc.) validated for whole-blood capillary samples, but this device has not received FDA 510(k) clearance for U.S. Sale, despite published validation data showing a correlation coefficient of r = 0.979 versus the reference immunoassay in 97 paired samples. [6]

Ordering 1,5-AG Through U.S. Reference Labs

The two major pathways available to U.S. Patients are:

1. Physician or telehealth provider order (most common) A licensed provider (including HealthRX clinicians) orders CPT 82985 through LabCorp, Quest Diagnostics, or a specialty metabolic lab. The patient goes to any phlebotomy draw site. Results return in 3 to 5 business days.

2. Direct-access lab services Several direct-to-consumer lab ordering platforms (e.g., Ulta Lab Tests, Walk-In Lab) list 1,5-AG / GlycoMark panels that route to LabCorp. These do not require a prescription in most U.S. States. Cash-pay pricing typically runs between $49 and $85 for the standalone test as of mid-2025.

Continuous Glucose Monitors as a Functional Proxy

CGM devices such as the Abbott FreeStyle Libre 3 and the Dexterity Dexcom G7 do not measure 1,5-AG, but they do measure the underlying phenomenon that drives 1,5-AG down: postprandial glucose excursions. A 2021 study in Diabetes Technology and Therapeutics (N=142) found that CGM-derived time-above-range (TAR greater than 180 mg/dL) correlated inversely with 1,5-AG at r = -0.74 (P<0.001). [7]

If you want at-home, real-time postprandial data today, a two-week blinded CGM trial is the closest functional equivalent to what 1,5-AG captures in a single blood draw. The two approaches are complementary: CGM maps which meals cause spikes; a follow-up 1,5-AG test quantifies the cumulative load of those spikes in a single reportable number.

Who Should Order GlycoMark (1,5-AG)?

The test is not part of routine annual labs for everyone. Specific clinical scenarios justify adding it.

Patients With Normal or Near-Normal HbA1c

People with HbA1c between 5.4% and 6.4% who report symptoms consistent with postprandial hyperglycemia (fatigue after meals, reactive hypoglycemia two hours post-meal, unexplained weight gain) may benefit from 1,5-AG testing. The American Diabetes Association's Standards of Medical Care in Diabetes acknowledges that postprandial glucose monitoring provides clinically relevant information beyond A1c in this gray zone. [8]

Post-Bariatric and GLP-1 Therapy Monitoring

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) reduce postprandial glucose excursions through delayed gastric emptying and glucose-dependent insulin secretion. 1,5-AG rises reliably as postprandial control improves. In a 24-week open-label trial of liraglutide 1.8 mg in 73 patients with type 2 diabetes, 1,5-AG increased from a mean of 7.2 to 14.1 mcg/mL, a change that reflected improved postprandial control more sensitively than the concurrent HbA1c reduction from 8.1% to 7.4%. That finding was published in Diabetes, Obesity and Metabolism. [9]

Patients on SGLT-2 Inhibitors: A Critical Caveat

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block the same renal transporter that mediates 1,5-AG reabsorption. The result is artificially low 1,5-AG values regardless of actual glucose control. The FDA product labeling and a 2013 analysis in Diabetes Care confirmed that SGLT-2 inhibitor use renders 1,5-AG uninterpretable as a glycemic marker. [10] Anyone taking an SGLT-2 inhibitor should not order GlycoMark. Use CGM or fructosamine instead.

Pregnancy and Pre-Conception Monitoring

Gestational glycemic control matters well before a fasting glucose reaches pre-diabetic thresholds. A prospective cohort of 459 pregnant women published in the American Journal of Obstetrics and Gynecology found that first-trimester 1,5-AG below 14 mcg/mL was associated with a 2.3-fold higher risk of gestational diabetes mellitus at 24 to 28 weeks, independent of pre-pregnancy BMI. [11] This suggests 1,5-AG may have a role in early identification of women at risk, though it is not yet incorporated into ACOG routine prenatal screening guidelines.

How to Interpret Your GlycoMark Result in Context

A single 1,5-AG number tells a partial story. Context matters.

Pairing 1,5-AG With Other Glycemic Markers

The most informative glycemic panel for metabolic health assessment combines:

• Fasting glucose (captures chronic fasting state)
• HbA1c (90-day average glucose)
• Fasting insulin (detects insulin resistance before glucose rises)
• 1,5-AG (recent postprandial load)

Each captures a different time window and a different aspect of glucose metabolism. A person could have a normal fasting glucose (85 mg/dL), a normal HbA1c (5.5%), and still have a 1,5-AG of 11 mcg/mL, signaling frequent after-meal excursions that the other markers did not flag.

Interpreting a Low Result When A1c Is Normal

This is the most clinically actionable scenario. A 2012 analysis published in Diabetes Care (N=2,208 from the ACCORD trial biorepository) found that in participants with A1c below 7.5%, low 1,5-AG was independently predictive of cardiovascular events over 5 years. [12] The authors concluded that 1,5-AG "provides prognostic information beyond HbA1c for cardiovascular outcomes in persons with type 2 diabetes," a finding with direct implications for precision cardiovascular risk stratification even in people with well-controlled traditional markers.

Dr. Elizabeth Selvin at Johns Hopkins, a leading researcher in glycemic biomarker epidemiology, stated in a 2014 review: "1,5-AG captures a dimension of hyperglycemia that other glycemic biomarkers do not, specifically the frequency and magnitude of glucose excursions above the renal threshold." That review appeared in Clinical Chemistry. [13]

Repeat Testing Frequency

Because 1,5-AG reflects only the past 7 to 14 days, re-testing every 4 to 8 weeks is appropriate when tracking a dietary or pharmacologic intervention. A 6-week interval allows two full marker turnovers. Annual testing is appropriate for metabolically healthy adults using it as a surveillance marker.

Factors That Affect 1,5-AG Independent of Glucose

Several non-glycemic variables can shift the result. Knowing them prevents misinterpretation.

Dietary 1,5-AG Content

1,5-AG is found in foods including wheat, soybeans, and certain fruits. Severe caloric restriction or fasting for more than 48 hours may transiently lower serum 1,5-AG by reducing dietary intake rather than by increasing urinary spillage. A controlled crossover study in 18 healthy volunteers documented a 12% decline in 1,5-AG after a 72-hour fast, unrelated to any change in glucose excursion frequency. [14] Standard pre-draw instructions (no fasting required beyond the routine 8-hour fast for a metabolic panel) are adequate.

Renal Impairment

Reduced glomerular filtration lowers the filtered load of both glucose and 1,5-AG, reducing competitive inhibition of reabsorption and artificially elevating 1,5-AG even when glucose control is poor. The test is considered unreliable in patients with an eGFR below 45 mL/min/1.73 m². Fructosamine or CGM should replace it in chronic kidney disease stage 3b or worse. The National Kidney Foundation's guidance on diabetes biomarker use in CKD addresses this limitation explicitly. [15]

Liver Disease and Pregnancy

Both conditions are associated with altered 1,5-AG metabolism. Advanced hepatic dysfunction reduces 1,5-AG synthesis, lowering serum levels independent of glucose control. In pregnancy, expanded plasma volume and altered renal thresholds can shift baseline values; interpretation should use pregnancy-specific reference data when available.

Practical Steps for HealthRX Patients

Getting a 1,5-AG test through HealthRX is straightforward. During your initial or follow-up metabolic panel visit, request the glycemic biomarker upgrade, which adds CPT 82985 to your standard panel. Your provider reviews the result alongside your fasting insulin, HbA1c, and fasting glucose and returns a written interpretation within your secure patient portal within 48 hours of the result posting.

If your 1,5-AG comes back below 14 mcg/mL and you are not on an SGLT-2 inhibitor, expect a follow-up recommendation for one of the following three pathways: a 14-day blinded CGM trial to identify the specific meal patterns driving excursions, a structured dietary consultation targeting postprandial glycemic load, or a GLP-1 receptor agonist evaluation if your clinical picture warrants pharmacologic support.

A 1,5-AG above 19 mcg/mL in a non-diabetic adult, paired with a normal fasting glucose and HbA1c below 5.7%, is a strong signal of intact postprandial glucose regulation. Repeat the test in 12 months as part of annual metabolic surveillance.